

Insert new claims, as follows:

D7
JN127
JN127

86. (NEW) The transdermal delivery system of claim 84 wherein said acrylic-based polymers include a C₄-C₁₂ alkyl acrylate.

87. (NEW) The transdermal delivery system of claim 86 wherein said acrylic-based polymers include a C₁-C₄ alkyl acrylate hardening monomer.

88. (NEW) The transdermal delivery system of claim 87 wherein said acrylic-based polymers include a functionalizing monomer.

89. (NEW) The transdermal delivery system of claim 88 wherein said acrylic-based polymers include a cross-linking agent.

90. (NEW) The transdermal delivery system of claim 84 wherein said at least one of said one or more drugs has a molecular weight of less than about 300 MW.

91. (NEW) The transdermal delivery system of claim 84 including from about 3% to 35% of said therapeutically effective amount of one or more drugs.

Su
f3
92. (NEW) A transdermal delivery system consisting essentially of a blend of;

(a) an acrylic-based polymer; and
(b) a therapeutically effective amount of a drug having a low molecular weight and being a liquid at or about room temperatures, wherein said system is substantially free of solvents selected from the group consisting of water and liquids having a normal boiling point
(i) below processing temperature and
(ii) equal to or greater than the normal boiling points of the low molecular weight drugs,

E3
Cont
D
Cont

Application No.: 08/883,075

Docket No.: BERTEK 3.0-025

whereby said transdermal drug delivery system, subsequent to processing, is free of said solvents.
